EUVIMEDEUVIMED entdecken
Kohortenstudie

L26/O-039 Impact of chemotherapy on ovarian reserve in premenopausal women with breast cancer treated with and without ovarian tissue cryopreservation for fertility preservation: a cohort study

M. Yde, L.B. Colmorn, A. Pinborg, J.L. Forman, I.M.H. Prietzel, C. Stern, L.H. Christensen, E.C. Larsen, A.T. Pedersen, K.T. Macklon

Human Reproduction · 01.07.2026 · 41 (Supplement_1)

DOI: 10.1093/humrep/deag083.039 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Human Reproduction, online erschienen am 08.07.2026. Verfasst von M. Yde und 9 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Study question How does chemotherapy affect ovarian reserve in premenopausal women with breast cancer, and how is this impacted by fertility preservation strategy and age at diagnosis? Summary answer Chemotherapy reduces ovarian reserve in women diagnosed with breast cancer, particularly among women who underwent ovarian tissue cryopreservation (OTC) and those of advanced reproductive age. What is known already Chemotherapy is gonadotoxic, potentially leading to infertility, premature ovarian insufficiency (POI), and related health consequences. Breast cancer is the most common cancer in women of reproductive age with increasing incidence. Many women have not completed family building at diagnosis. Over recent decades, increasing emphasis has been placed on fertility preservation (FP), including ovarian tissue-, embryo- and oocyte cryopreservation. Few large studies have prospectively evaluated the effect of chemotherapy on ovarian reserve in breast cancer patients, using both AMH and AFC, and no large studies have assessed the impact by choice of FP. Study design, size, duration In this cohort study, we included 152 premenopausal women diagnosed with breast cancer who received FP counselling at Rigshospitalet, Copenhagen University Hospital, between 1 January 2018 and 31 August 2023, with regular follow-up for up to 24 months after completion of chemotherapy. Participants/materials, setting, methods Women aged 18-42 years scheduled for FP counselling prior to chemotherapy were included. Exclusion criteria were previous chemotherapy, oophorectomy, and death or emigration within two years of inclusion. Medical and gynecological history and oncological treatment plans were recorded. Ovarian reserve was assessed by antimüllerian-hormone (AMH) and antral-follicle-count (AFC) at baseline and at 6, 12, and 24 months post-chemotherapy. Changes over time were analyzed using linear-mixed-models, adjusting for age and use of hormonal contraception at baseline. Main results and the role of chance Of 152 women, 57 underwent OTC for FP, while 95 underwent oocyte or embryo cryopreservation or no FP. Baseline median AMH was 13.9 [95% CI: 10.7, 18.1] pmol/L among women not undergoing OTC and 13.3 [10.9, 16.3] pmol/L among those undergoing OTC. A marked reduction in both AMH and AFC was observed after chemotherapy, with partial recovery within two years after treatment. The reduction was more pronounced, and recovery more limited, in women with OTC and in those of advanced reproductive age (≥35 years). Compared to baseline, median AMH was reduced by 90% [95% CI: 93%, 85%] at 6 months and 74% [82%, 61%] at 24 months in women without OTC, and by 92% [95% CI: 95%, 86%] and 85% [90%, 77%] in women with OTC. Among women aged ≤34 years, AMH at 24 months was reduced by 68% [95% CI: 79%, 51%] in those without OTC and 77% [85%, 63%] in those with OTC, whereas among women aged ≥35 years the reductions were 81% [95% CI: 93%, 51%] and 94% [97%, 90%], respectively. Similar patterns, however, not as profound was seen for AFC. There was no statistically significant difference in menstrual cycle recovery between those with and without OTC. Limitations, reasons for caution Not all women completed assessments at all three follow-up visits, likely due to emotional exhaustion, hospital fatigue, fear of additional visits, or changing reproductive intentions. Furthermore, the reduction in ovarian reserve may also to some extent reflect the natural age-related reductions in ovarian reserve. Wider implications of the findings These findings will support counselling women with breast cancer about chemotherapy related ovarian damage and the need for FP. It will help weighing risks and benefits of FP options, to avoid possible unnecessary, costly treatments that may further compromise ovarian reserve and potentially increase POI risk and related health consequences. Trial registration number No

Zitieren

APA

Yde, M., Colmorn, L., Pinborg, A., Forman, J., Prietzel, I., Stern, C., Christensen, L., Larsen, E., Pedersen, A., & Macklon, K. (2026). L26/O-039 Impact of chemotherapy on ovarian reserve in premenopausal women with breast cancer treated with and without ovarian tissue cryopreservation for fertility preservation: a cohort study. Human Reproduction, 41(Supplement_1). https://doi.org/10.1093/humrep/deag083.039

Vancouver

Yde M, Colmorn L, Pinborg A, Forman J, Prietzel I, Stern C, et al. L26/O-039 Impact of chemotherapy on ovarian reserve in premenopausal women with breast cancer treated with and without ovarian tissue cryopreservation for fertility preservation: a cohort study. Human Reproduction. 2026;41(Supplement_1). doi:10.1093/humrep/deag083.039

BibTeX
@article{Yde2026,
  author = {Yde, M. and Colmorn, L.B. and Pinborg, A. and Forman, J.L. and Prietzel, I.M.H. and Stern, C. and Christensen, L.H. and Larsen, E.C. and Pedersen, A.T. and Macklon, K.T.},
  title = {L26/O-039 Impact of chemotherapy on ovarian reserve in premenopausal women with breast cancer treated with and without ovarian tissue cryopreservation for fertility preservation: a cohort study},
  journal = {Human Reproduction},
  year = {2026},
  volume = {41},
  number = {Supplement_1},
  doi = {10.1093/humrep/deag083.039}
}
Kostenlos starten →